Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
HIPAA stands for the Health Insurance Portability and Accountability Act of 1996. It is a U.S. healthcare legislation to direct how patient data is used and includes two major rules which are privacy and security of data. The privacy rule protects people's rights to privacy and security rule determines how to protect people's privacy. According to the HIPAA Security Rule, it ensures that protected health information has three characteristics: confidentiality, availability, and integrity. Confidentiality indicates keeping the data confidential to prevent data loss or individuals who are unauthorized to access that protected health information. Availability allows people who are authorized to access the systems and networks when and where that information is in fact needed, such as natural disasters. In cases like this, protected health information is mostly backed up on to a separate server or printed out in paper copies, so people can access it. Lastly, integrity ensures not using inaccurate information and improperly modified data due to a bad design system or process to protect the permanence of the patient data. The consequences of using inaccurate or improperly modified data could become useless or even dangerous. Health Organizations of HIPAA also created administrative safeguards, physical safeguards, technical safeguards, to help protect the privacy of patients.
== History == Desmethylprodine was first synthesized in 1947 at Hoffman-LaRoche Laboratories by Albert Ziering and John Lee. They found that it produced effects similar to morphine when administered to rats. Ziering had been searching for synthetic painkillers that were less addictive than morphine. The new drug was a slight variant of pethidine. It was found to be no more effective than pethidine and was never marketed. This research produced the analgesic alphaprodine (Nisentil, Prisilidine), a very closely related compound. In the United States, MPPP is now in Schedule I of the Controlled Substances Act with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.87 for the hydrochloride. It is listed under the Single Convention on Narcotic Drugs and is controlled in most countries in the same fashion as is morphine.
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients. Both elbasvir and grazoprevir were developed by Merck & Co. The US Food and Drug Administration (FDA) approved the drug in January 2016.
However, up to 5% of individuals with CAIS do not have an AR mutation. The receptor in question is encoded by the AR gene located on the X chromosome at Xq11–12. At least 15 different mutations were known in 2003, and they are all recessive, which makes the disease follow X-linked recessive inheritance. Immature sperm cells in the testes do not mature past an early stage, as sensitivity to androgens is required in order for spermatogenesis to complete. Germ cell malignancy risk, once thought to be relatively high, is now thought to be approximately 2%. Wolffian structures (the epididymides, vasa deferentia, and seminal vesicles) are typically absent, but will develop at least partially in approximately 30% of cases, depending on which mutation is causing the CAIS. The prostate, like the external male genitalia, cannot masculinize in the absence of androgen receptor function, and thus remains in the female form. The Müllerian system typically regresses the same way it does in unaffected male fetuses due to anti-Müllerian hormone originating from the Sertoli cells of the testes. Thus, people with CAIS, despite having a vagina due to androgen insensitivity, are born without fallopian tubes, a cervix, or a uterus, and the vagina ends "blindly" in a pouch. Müllerian regression does not fully complete in some cases of CAIS, resulting in Müllerian "remnants". Although rare, a few cases of people diagnosed with CAIS and having Müllerian structures have been reported. In one exceptional case, a 22-year-old with CAIS was found to have a cervix, uterus, and fallopian tubes.
Sources: en.wikipedia.org
For instance, whereas the AR activity of testosterone is greatly potentiated by local conversion via 5α-reductase into DHT in tissues where 5α-reductase is expressed, an AAS that is not metabolized by 5α-reductase or is already 5α-reduced, such as DHT itself or a derivative (like mesterolone or drostanolone), would not undergo such potentiation in said tissues. Moreover, nandrolone is metabolized by 5α-reductase, but unlike the case of testosterone and DHT, the 5α-reduced metabolite of nandrolone has much lower affinity for the AR than does nandrolone itself, and this results in reduced AR activation in 5α-reductase-expressing tissues. As so-called "androgenic" tissues such as skin/hair follicles and male reproductive tissues are high in 5α-reductase expression, while skeletal muscle is virtually devoid of 5α-reductase, this may primarily explain the high myotrophic–androgenic ratio and dissociation seen with nandrolone, as well as with various other AAS. Aside from 5α-reductase, aromatase may inactivate testosterone signaling in skeletal muscle and adipose tissue, so AAS that lack aromatase affinity, in addition to being free of the potential side effect of gynecomastia, might be expected to have a higher myotrophic–androgenic ratio in comparison. In addition, DHT is inactivated by high activity of 3α-HSD in skeletal muscle (and cardiac tissue), and AAS that lack affinity for 3α-HSD could similarly be expected to have a higher myotrophic–androgenic ratio (although perhaps also increased long-term cardiovascular risks).
== Organic heterocycles and polymers == Radical cations figure prominently in the chemistry and properties of conducting polymers. Such polymers are formed by the oxidation of heterocycles to give radical cations, which condense with the parent heterocycle. For example, polypyrrole is prepared by oxidation of pyrrole using ferric chloride in methanol:
== Comparison to the first Cold War == An academic Barry Buzan wrote in the International Politics journal article that, similar to the original Cold War, the Second Cold War is deterred from turning into a "hot" war between superpowers due to the threat of mutually assured destruction and nuclear deterrence. Buzan further determined that proxy wars and half-proxy wars are found both in the first Cold War and the Second Cold War. Historian Hope M. Harrison stated in 2023 that the Cold War and the "new Cold War" between Russia and the West both have an ideological component. She said that former US presidents had spoken of the Cold War as a conflict between democracy and tyranny, Western leaders such as US president Joe Biden have called the war in Ukraine a "battle between democracy and autocracy". Putin, she says "finds the West decadent, devoid of morals and trying to impose itself on Ukraine, Russia and the rest of the world", adding that "[c]onservative parties around the world join him in criticising 'liberal extremists'". Historian Antony Beevor stated in October 2022 that "it is no longer [about] the old divide between left and right" but rather "a change in the direction of autocracy versus democracy", a change made apparent by the Russian invasion of Ukraine; in his opinion, this cold war is "much scarier" than the first, as "one of the most worrying aspects" of the new cold war is a total disregard for diplomatic agreements.
Sources: en.wikipedia.org
=== Etymology === The name estradiol derives from estra-, Gk. οἶστρος (oistros, literally meaning "verve or inspiration"), which refers to the estrane steroid ring system, and -diol, a chemical term and suffix indicating that the compound is a type of alcohol bearing two hydroxyl groups.
=== Affinity selection-mass spectrometry === While adoption of affinity selection-mass spectrometry (AS-MS) has led to an expansion of assay formats, the general technique follows a simple scheme. Protein targets are incubated with small molecules to allow for the formation of stable ligand-protein complexes, unbound small molecules are removed from the mixture, and the components of remaining ligand-protein complexes are analyzed using mass spectrometry. The bound ligands identified are then categorized as hits and can be used to provide a starting point for lead generation. Since AS-MS measures binding in an unbiased manner, a hit does not need to be tied to a functional readout, opening the possibility of identifying drugs that act beyond active sites, such as allosteric modulators and chemical chaperones, all in a single assay. Because small molecules can be directly identified by their exact mass, no derivatization is needed to confirm the validity of a hit. Among derivatization- and label-free approaches, AS-MS has the unique advantage of being amenable to the assessment of multiple test compounds per experiment—as many as 20,000 compounds per experiment have been reported in the literature, and one group has reported assaying chemical libraries against heterogeneous protein pools. The basic steps of AS-MS are described in more detail below.
These include hypothetical machines that manipulate individual atoms and machines with organism-like self-replicating abilities, mobility, ability to consume food, and so forth. These are quite different from devices that merely (as defined above) "guide chemical reactions by positioning reactive molecules with atomic precision". Because synthetic molecular assemblers have never been constructed and because of the confusion regarding the meaning of the term, there has been much controversy as to whether "molecular assemblers" are possible or simply science fiction. Confusion and controversy also stem from their classification as nanotechnology, which is an active area of laboratory research which has already been applied to the production of real products; however, there had been, until recently, no research efforts into the actual construction of "molecular assemblers". Nonetheless, a 2013 paper by David Leigh's group, published in the journal Science, details a new method of synthesizing a peptide in a sequence-specific manner by using an artificial molecular machine that is guided by a molecular strand. This functions in the same way as a ribosome building proteins by assembling amino acids according to a messenger RNA blueprint. The structure of the machine is based on a rotaxane, which is a molecular ring sliding along a molecular axle. The ring carries a thiolate group, which removes amino acids in sequence from the axle, transferring them to a peptide assembly site.
Another rationale for including snake flesh was the widespread belief that snakes contained an antidote to protect themselves against being poisoned by their own venom. Thinking by analogy, Henry Grosmont also thought of theriac as a moral curative, the medicine "to make a man reject the poisonous sin which has entered into his soul". Because the plague, most notably the Black Death, was believed to have been sent by God as a punishment for sin and had its origins in pestilential serpents that poisoned the rivers, theriac was a particularly appropriate remedy or therapeutic. By contrast, Christiane Fabbri argues that theriac, which very frequently contained opium, actually did have palliative effect against pain and reduced coughing and diarrhea.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.